Drug Trial Radar · NCT06665412
Efficacy and Safety of Dose Redution of Radotinib as a First Line Treament in Ph+ CML
Last checked: Nov 19, 2026Latest source record: Sep 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
169
Actual
Start
Oct 24, 2024
Primary completion
Jul 15, 2027
Study completion Dec 31, 2027
Sponsor
- Lead sponsor
- Il-Yang Pharm. Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Oct 30, 2024
Design
- Study type
- Observational
- FDA-regulated drug
- No
- Who can join
- All sexes, from 19 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of this observational study is to learn about the efficacy and safety profile when Radotinib dose redution is performed in Ph+ CML subjects. The main efficacy is checked by MMR rate by 12 months from IP treatment.
Conditions
- Chronic Phase Ph+ Chronic Myeloid Leukemia
Interventions
Radotinib HydrochlorideDrug
200mg BID, every day up to 12months
Primary outcomes
What the sponsor says the trial is designed to measure.
- To evaluate MMR rate up to 12months following the treatment of RadotinibTime frame: up to 12months
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Keimyung University Daegu Dongsan Hospital
Daegu, South Korea
Hallym University Sacred Heart Hosptial
Anyang-si, Gyeonnggi-do, South Korea
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.